Extended Data Table 4 Proportion of participants achieving a ≥ 0.5 reduction from baseline in RQLQ score at weeks 2 and 4

From: Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial

  1. aData shown are n (%), unless otherwise indicated. The proportion difference between groups and its 95% CI were computed by normal approximation method. P values were two-sided and nominal, without adjustments for multiple comparisons. Missing data was imputed as non-response. RQLQ, Rhinoconjunctivitis Quality of- Life Questionnaire; CI, confidence interval.
  2. Source data
Back to article page